PTC therapeutics agrees with the overall objectives of the proposed Pharmaceutical Package (proposed Regulation and Directive): As a company we are striving to develop therapies for people living with a rare disease and as such we want to contribute to creating an innovative and competitive EU healthcare ecosystem with standards that can compete at a global level.
PT
PTC Therapeutics
Company · United States · EU Transparency Register 463256021850-41
3
positions filed
in the 583 files tracked
2
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1048 companies & groups on this site, they rank #443 by legislative files engaged — a count of participation, not a measure of influence.
0.5
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2016
in the register since
Declares membership of
- EuropaBio https://www.europabio.org/
- EUCOPE https://www.eucope.org/
- TRANSFORM https://transformalliance.eu/
- European Group of Experts on OMP Incentives https://od-expertgroup.eu/
- EU Biotech and Life Sciences Alliance. https://biolifesciences.eu/
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Companies & groups
- Head office
- Warren, United states
- EU office
- Steinhausen
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track PTC in PolicySpeak: request access →
Work at PTC Therapeutics? so we know who speaks for it.
Their record over time
PTC Therapeutics filed 3 positions between 7 Dec 2020 and 26 Jun 2023, across 2 of the 583 legislative files tracked here.
2020 · 1 filed2023 · 2 filed
What they argued
PTC therapeutics agrees with the overall objectives of the proposed Pharmaceutical Package (proposed Regulation and Directive): As a company we are striving to develop therapies for people living with a rare disease and as such we want to contribute to creating an innovative and competitive EU healthcare ecosystem with standards that can compete at a global level.
The OMP Regulation was introduced to stimulate research in rare diseases. PTC Therapeutics believes the Regulation has been a successful European regulatory instrument as it not only led to an increase in the number of orphan drugs but also put a spotlight on the high unmet medical needs of rare disease patients.PTC recognised that after 20 years it is a good moment to take stock of the effectiveness of the…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put PTC Therapeutics next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 52.
Is this your organization?
Everything on this page comes from PTC Therapeutics’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.